Gene Therapy’s Next Target: Our Microbes

CRISPR pioneer Jennifer Doudna recently co-launched an initiative focused on microbial gene editing, but French biotech Eligo has been diligently working on this for 10 years. 

Microbes, The Next Frontier For Gene Editing • Source: Shutterstock

When WIRED featured Jennifer Doudna's microbial gene editing project in late 2023, it brought star power to a nascent field. However, a Paris-based biotech has been quietly advancing this research and is set to move into clinical trials next year.

Founded in 2014 as a spin-off from MIT and Rockefeller University, Eligo took a unique approach to CRISPR, focusing on...

More from Innovation

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

More from In Vivo